JPRN-UMIN000012700已完成2 期
Phase II study of a BD-HDM regimen for multiple myeloma patients - Bomb-MM01
ational Hospital Organization Disaster Medical Center of Japan0 个研究点目标入组 96 人开始时间: 2013年12月25日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 96
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 65years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •The exclusion criteria were a serum creatinine level2.05 mg/dL at time of high-dose therapy (HDT), liver dysfunction (e.g., a serum total bilirubin level2.0 mg/dL, or serum aspartate/alanine aminotransferase or alkaline phosphatase levels more than 2.5 times the upper limit of normal), grade 3 or worse peripheral neuropathy, significant comorbidity that would preclude ASCT, poor performance status (grade 3), and a history of any other malignancy with the exception of basal cell carcinoma and stage I cervical cancer.
研究者
相似试验
已完成
不适用
Phase II study of a BD-HDM regimen for multiple myeloma patientsmultiple myelomaJPRN-UMIN000005674ational Hospital Organization Disaster Medical Center of Japan10
进行中（未招募）
1 期
Global study to find the recommended dose of HDM201 added to chemotherapy and to assess safety and efficacy in patients with newly diagnosed or relapsed/refractory acute myeloid leukemiaRelapsed refractory (R/R) or newly diagnosed acute myeloid leukemia (AML)EUCTR2018-003107-19-FRovartis Pharma AG
进行中（未招募）
1 期
Global study to find the recommended dose of HDM201 added to chemotherapy and to assess safety and efficacy in patients with newly diagnosed or relapsed/refractory acute myeloid leukemiaRelapsed refractory (R/R) or newly diagnosed acute myeloid leukemia (AML)EUCTR2018-003107-19-DEovartis Pharma AG
进行中（未招募）
1 期
Global study to find the recommended dose of HDM201 added to chemotherapy and to assess safety and efficacy in patients with newly diagnosed or relapsed/refractory acute myeloid leukemiaRelapsed refractory (R/R) or newly diagnosed acute myeloid leukemia (AML)MedDRA version: 21.1Level: PTClassification code 10000880Term: Acute myeloid leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-003107-19-ITOVARTIS PHARMA AG
招募中
不适用
Delivering radiation therapy to chest lymphomas(cancer) in deep inspiration.CTRI/2018/07/014847Tata Memorial Center